Avastimab 100 mg Injection

Avastimab 100 mg Injection contains bevacizumab 100 mg, a monoclonal antibody used in specific cancer treatment regimens. It works by inhibiting VEGF and reducing the formation of new blood vessels that can support tumor growth. The product is supplied as a 100 mg/4 mL injection for intravenous infusion.

BUY NOW

Bevacizumab binds to vascular endothelial growth factor and inhibits its biological activity, thereby reducing tumor-associated angiogenesis. Avastimab is used in treatment regimens for cancers including colorectal, non-small-cell lung, kidney, brain, ovarian, and cervical cancers. Each 4 mL vial contains 100 mg of bevacizumab, giving a concentration of 25 mg/mL. Avastimab 100 mg Injection is marketed by RPG Life Sciences and should be refrigerated at 2°C–8°C without freezing.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 100 mg
Concentration 25 mg/mL
Pack Size 4 mL vial
Dosage Form Injection
Storage 2°C–8°C

Product Also Known As

Avastimab 100 mg Injection, Avastimab 100 mg/4 mL, Avastimab 100 Injection, Avastimab Bevacizumab Injection, Bevacizumab 100 mg Injection, Bevacizumab 100 mg/4 mL